Equities

ALVAL

FR0013254851

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:35:07 2024-05-03 am EDT			5-day change	1st Jan Change
4.13 ^EUR	+0.49%		+5.90%	-17.40%

Apr. 26	Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 03	Valbiotis: launch of Valbiotis PRO Cholesterol in May	CF

VALBIOTIS : Rapport financier semestriel 2023

October 15, 2023 at 02:21 am EDT

Rapport financier semestriel 2023

15 Oct 2023 08:00 CEST

Issuer

VALBIOTIS S.A.

Rapport financier semestriel 2023

Source

VALBIOTIS

Provider

Euronext

Company Name

VALBIOTIS

ISIN

FR0013254851

Symbol

ALVAL

Market

Euronext Growth

Attachments

Original Link
Original Document
Permalink

Disclaimer

Valbiotis SA published this content on 15 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 October 2023 06:20:31 UTC.

Latest news about VALBIOTIS

Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 26	CI
Valbiotis: launch of Valbiotis PRO Cholesterol in May	Apr. 03	CF
Valbiotis: capital increase successfully completed	Dec. 22	CF
Valbiotis: 15 ME capital increase	Dec. 12	CF
Valbiotis' Plant Extract Receives New Dietary Ingredient Status from US FDA	Dec. 12	MT
Valbiotis SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Valbiotis: share price rises on success of clinical study	23-09-12	CF
Valbiotis SA Presents the Full Results of the Phase II/III REVERSE-IT Study: Impressive Efficacy of TOTUM 63 Against Prediabetes and the Early Stages of Type 2 Diabetes, a First for a Non-drug Active Substance	23-09-11	CI
VALBIOTIS : Invest Securities confirms its recommendation	23-07-17	CF
Global markets live: BP, Walt Disney, Amazon, PepsiCo, Delta Airlines....	23-07-13
Valbiotis: share price up, broker in support	23-05-25	CF
VALBIOTIS : Oddo BHF raises its target price	23-05-25	CF
Valbiotis: share price soars, broker adjusts target	23-05-23	CF
VALBIOTIS : promising study, Invest Sec. raises its target	23-05-23	CF
Valbiotis: 'major' breakthrough in type 2 diabetes	23-05-22	CF
Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM-63	23-05-22	CI
Global markets live: Deliveroo, Adobe, Berkshire Hathaway, First republic Bank, Robinhood Markets...	23-03-16
Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
Valbiotis SA Announces the Last Visit of the Last Patient in the Phase II/III REVERSE-IT Study on TOTUM•63, in Partnership with Nestlé Health Science	23-03-13	CI
Global markets live: GM, Pfizer, Exxon, UBS, Boeing...	23-01-31
Valbiotis: encouraging results in hypertension	23-01-30	CF
Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM--854 Clinical Study, Against High Blood Pressure	23-01-30	CI
Valbiotis SA Announces the Signature of a Research Partnership in Intestinal Microbiota With the MEDIS Unit From the Clermont Auvergne University	22-12-14	CI
Valbiotis SA announced that it has received €9.7 million in funding	22-11-08	CI
Valbiotis SA Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hypercholesterolemia	22-10-03	CI

Chart VALBIOTIS

Duration

Period

More charts

Company Profile

VALBIOTIS is a French Research & Development company committed to scientific innovation for the prevention and control of metabolic diseases. Valbiotis specializes in the development of innovative nutritional solutions for cardio-metabolic disease prevention and nutritional support for patients. The products are intended for food and pharmaceutical industries. Valbiotis is essentially intervening in the prevention of type 2 diabetes, NASH (non-alcoholic steatohepatitis), obesity and cardiovascular diseases. VALBIOTIS has established numerous partnerships with academic centers of excellence in France and overseas, including the University of La Rochelle, the CNRS, and the Clermont Auvergne University in Clermont-Ferrand where the company has opened a secondary school. With these agreements, since its inception Valbiotis has benefited from a strong leverage thanks notably to experts and technical partners involved in its projects.

Sector

Biotechnology & Medical Research

Calendar

2024-06-24 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for VALBIOTIS

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.13 EUR

Average target price

10.07 EUR

Spread / Average Target

+143.75%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VALBIOTIS	-17.40%	70.17M
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-4.36%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.16B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B

Bio Therapeutic Drugs